Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533

The utility of circulating tumor DNA (ctDNA) analyses has not been established in the risk stratification of Wilms tumor (WT). We evaluated the detection of ctDNA and selected risk markers in the serum and urine of patients with WT and compared findings with those of matched diagnostic tumor samples...

Descripción completa

Detalles Bibliográficos
Autores principales: Madanat-Harjuoja, Laura M., Renfro, Lindsay A., Klega, Kelly, Tornwall, Brett, Thorner, Aaron R., Nag, Anwesha, Dix, David, Dome, Jeffrey S., Diller, Lisa R., Fernandez, Conrad V., Mullen, Elizabeth A., Crompton, Brian D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462535/
https://www.ncbi.nlm.nih.gov/pubmed/35580298
http://dx.doi.org/10.1200/JCO.22.00098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462535/
https://www.ncbi.nlm.nih.gov/pubmed/35580298
http://dx.doi.org/10.1200/JCO.22.00098

Ejemplares similares